Influence of Prior Heart Failure Hospitalization on Cardiovascular Events in Patients with Reduced and Preserved Ejection Fraction Bello et al: Effect of HF Hospitalization on CV Events

[1]  V. Roger.  Epidemiology of Heart Failure , 2013, Circulation research.

[2]  David D McManus,et al.  Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. , 2013, The American journal of medicine.

[3]  A. Keren,et al.  Heart Failure and Preserved Left Ventricular Function: Long Term Clinical Outcome , 2012, PloS one.

[4]  Christina Lindahl,et al.  Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. , 2009, Journal of the American College of Cardiology.

[5]  E. Braunwald,et al.  Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction , 2009, Journal of the American College of Cardiology.

[6]  Karl Swedberg,et al.  Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure , 2007, Circulation.

[7]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[8]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[9]  Serguei V. S. Pakhomov,et al.  Systolic and diastolic heart failure in the community. , 2006, JAMA.

[10]  Peter C Austin,et al.  Outcome of heart failure with preserved ejection fraction in a population-based study. , 2006, The New England journal of medicine.

[11]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[12]  Luigi Tavazzi,et al.  Acute Heart Failure Syndromes: Current State and Framework for Future Research , 2005, Circulation.

[13]  J. McMurray,et al.  Heart failure with preserved left ventricular systolic function: a hospital cohort study , 2005, Heart.

[14]  P. McCullough,et al.  Outcomes and prognostic factors of systolic as compared with diastolic heart failure in urban America. , 2005, Congestive heart failure.

[15]  B. Yawn,et al.  Trends in heart failure incidence and survival in a community-based population. , 2004, JAMA.

[16]  K. Swedberg,et al.  Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. , 2004, European heart journal.

[17]  J. Parner,et al.  N‐terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF) , 2004, European journal of heart failure.

[18]  S. Yusuf,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial , 2004 .

[19]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[20]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[21]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[22]  Harlan M Krumholz,et al.  The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. , 2003, Journal of the American College of Cardiology.

[23]  P. Varadarajan,et al.  Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions: results from a cohort of 2,258 hospitalized patients. , 2003, Journal of cardiac failure.

[24]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[25]  J. Gardin,et al.  Outcome of Congestive Heart Failure in Elderly Persons: Influence of Left Ventricular Systolic Function: The Cardiovascular Health Study , 2002, Annals of Internal Medicine.

[26]  E. Antman.  Clinical trials in cardiovascular medicine. , 2001, Circulation.

[27]  R. Collins,et al.  Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials , 2001, The Lancet.

[28]  D. Behar,et al.  Long‐term prognosis of acute pulmonary oedema — an ominous outcome , 2000, European journal of heart failure.

[29]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[30]  D. Levy,et al.  Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. , 1999, Journal of the American College of Cardiology.

[31]  H. Krumholz,et al.  Admission to hospitals with on-site cardiac catheterization facilities :impact on long-term costs and outcomes. , 1998, Circulation.